Uptake Rate of Risk-reducing Salpingo-oophorectomy and Surgical Outcomes of Female Germline BRCA1/2 Mutation Carriers: A Retrospective Cohort Study at a Tertiary Institutional Hospital in Korea

Background: This study investigated the uptake rate of risk-reducing salpingo-oophorectomy (RRSO) and surgical outcomes of germline BRCA1/2 mutation carriers at Seoul National University Hospital (SNUH). We examined records of 824 women who underwent germline BRCA1/2 gene testing at SNUH between 2005 and 2020. Among them, we identified women with a pathogenic mutation on either the BRCA1 or the BRCA2 gene and excluded ovarian cancer patients. Characteristics of participants who underwent RRSO (RRSO group) were compared to those who did not (non-RRSO group). Surgical outcomes and pathologic results were investigated in the RRSO group. Results: : There were 117 BRCA1/2 mutation carriers included in this analysis. The uptake rate of RRSO was 70.1% (82/117). Older age (mean: 48.8 vs. 42.1 years; P = 0.002) and higher employment rate (65.9% vs. 14.3%; P < 0.001) were observed in the RRSO group than in the non-RRSO group. However, no differences in other factors such as personal and family history of breast cancer were observed between the two groups. In the RRSO group, the median time interval between the genetic test and RRSO was 10.0 months, and there were three (3.7%) incidental cases of high-grade serous carcinoma. However, one patient in the non-RRSO group developed primary peritoneal cancer after 103.8 months of surveillance. Conclusions: : The uptake rate of RRSO in BRCA1/2 mutation carriers was about 70%. Considering incidental cancer cases in women without abnormal findings on preoperative evaluation, it would be recommended to perform RRSO soon after the genetic test.